Latest News and Press Releases

Oslo, 27 April 2017: Photocure ASA (OSE: PHO), held its annual general meeting on 27 April 2017 at 17:00 hours (CET). All proposals were resolved as presented in the notice convening the general...

Data on US Registry Study for BLC(TM) with Cysview/Hexvix will also be Presented at AUA Oslo, Norway, April 26, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that results from the BLFC...

 Oslo, 24 April 2017: Photocure ASA (OSE: PHO). Bente-Lill Bjerkelund Romøren has as chairperson of the board of directors of PHO received proxies to vote for 1,389,360 shares at the annual general...

 Oslo, 24 April 2017: Photocure ASA (OSE: PHO). Hans Peter Bøhn has received proxies to vote for 1,545,735 shares at the annual general meeting of PHO on 27 April 2017 (the "AGM"), representing...

On 6 April 2017 Kjetil Hestdal, President and CEO of Photocure ASA, purchased 5 000 Photocure shares at a price of NOK 28.00 each. Kjetil Hestdal now holds 133 873 shares and 92 500 options in...

Oslo, 6 April 2017: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2016. The annual accounts and annual report for the financial year 2016 are...

Oslo, 6 April 2017: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 27 April 2017 at 17:00 hours (CET). The notice...

Following non-conclusive partnering discussions, the company will assess further strategic alternatives for Cevira and Visonac Company still to focus on urology franchise, with continued commitment...

Oslo, Norway, 15 February 2017: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 10 % to NOK...

Oslo, Norway, February 8th  2017, Photocure ASA announced today a publication in the Scandinavian Journal of Urology, describing a vision for improving outcomes for patients with non-muscle-invasive...